All news

© GettyImages/Artur

NPD Gallery: Technology Insider

By Jane Byrne

We track developments and launches in process engineering tools and research components over the past few weeks.

Pic:getty/hailshadow

Developing vaccines against Epstein-Barr virus

By Rachel Arthur

Last week the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a clinical trial to investigate a preventative vaccine for Epstein-Barr virus (EBV). It’s part of growing efforts to create...

Pic:getty/chaluk

Matica Bio opens new Texas cell and gene therapy facility

By Rachel Arthur

CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

Pic:getty/richarddrury

Nurturing biotech in Europe: EuropaBio sets out recommendations

By Rachel Arthur

EU systems need to become more streamlined to help bring novel technologies to market - which would in turn encourage investment and activity in healthcare biotech, says EuropaBio as it publishes key policy recommendations for the sector.

Pic:getty/marianvejcik

CPHI NORTH AMERICA 2022

US pharma hubs: The rising stars to watch

By Rachel Arthur

CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.

Pic:getty/oatawa

Astorg to acquire CordenPharma from ICIG

By Rachel Arthur

Astorg will acquire CDMO CordenPharma from ICIG: noting strong organic growth for the CDMO thanks to its position in fast-growing drug modalities such as mRNA vaccines, peptides and high-potency compounds notably for oncology therapeutics.

Pic:getty/jonathankitchen

Merck Q1: Keytruda sales up 23%

By Rachel Arthur

Merck’s cancer drug Keytruda continues to grow: helping Merck record ‘robust top-line and bottom-line growth’ across the company in Q1 2022.

© GettyImages/Olivier Le Moal

Amneal secures second US biosimilars approval

By Jane Byrne

Last week saw the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for bevacizumab-maly, a biosimilar referencing Avastin, the Roche/Genentech product.